Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648949 | 0.85 | PTPN1 (0.45) | PTPN1HDAC8NAMPTALDH1A1TSHR | |
| SCHEMBL2601969 | 0.81 | NAMPT (0.53) | NAMPTALDH1A1TSHRMAPK1LMNA | |
| SCHEMBL4803652 | 0.81 | PTPN1 (0.42) | PTPN1HDAC8ALDH1A1TSHRLMNA | |
| SCHEMBL9033817 | 0.78 | HDAC8 (0.64) | PTPN1HDAC8ALDH1A1 | |
| SCHEMBL9033831 | 0.78 | HDAC8 (0.64) | PTPN1HDAC8ALDH1A1 | |
| SCHEMBL6238826 | 0.77 | HDAC8 (0.70) | PTPN1HDAC8NAMPT | |
| SCHEMBL3562005 | 0.76 | F10 (0.47) | PTPN1HDAC8ALDH1A1LMNAHPGD | |
| SCHEMBL9033407 | 0.75 | HDAC8 (0.53) | PTPN1HDAC8NAMPT | |
| SCHEMBL9033397 | 0.75 | HDAC8 (0.53) | PTPN1HDAC8NAMPT | |
| SCHEMBL28496847 | 0.75 | SMN1; SMN2 (0.56) | ALDH1A1TSHRMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | PTPN1 1082/4885HDAC8 1207/4885NAMPT 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.